{"entity":{"id":"nct07203053","kind":"trial","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","aka":["START-lung"],"tldr":"A phase 2 trial of tarlatamab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","summary":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 is a phase 2, interventional study registered as NCT07203053 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 48 participants, started 2026-04-15 and due to reach its primary completion in 2029-10. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Cancer. Primary outcome: Overall survival rate at 12 months (12-month OS). Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed ES-SCLC\". Sites: France, Greece, Italy, Spain, Switzerland. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07203053","url":"https://clinicaltrials.gov/study/NCT07203053"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07203053","phase":"2","setting":"A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","sponsor":"ETOP IBCSG Partners Foundation","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07203053/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}